{"transactions":[{"id":718201,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":61378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.33,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":61378},"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718200,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":117.7029,"value":376649.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":244883,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718199,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":6153,"price":116.9937,"value":719862.2361,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":248083,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718198,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":7971,"price":115.8171,"value":923178.1041,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":254236,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718197,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":51375,"price":114.7696,"value":5896288.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":262207,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718196,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":4110,"price":114.1875,"value":469310.625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":313582,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718195,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":112.7881,"value":124066.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":317692,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718194,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1700,"price":111.5671,"value":189664.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":318792,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718193,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":110.5397,"value":165809.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":320492,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718192,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":61378,"price":5.33,"value":327144.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."}],"balance_after":321992,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":751914,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T11:30:03.000Z","date":"2026-06-02","kind":"exercise","planned":false,"acquired":false,"shares":12653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":12653},"source":{"system":"sec-edgar","filing":"0001193125-26-254589","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526254589/ownership.xml","form_type":"4"}},{"id":751913,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T11:30:03.000Z","date":"2026-06-02","kind":"exercise","planned":false,"acquired":true,"shares":12653,"price":2.08,"value":26318.24,"ownership":{"direct":true},"balance_after":260241,"source":{"system":"sec-edgar","filing":"0001193125-26-254589","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526254589/ownership.xml","form_type":"4"}},{"id":772218,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-19T11:30:05.000Z","date":"2026-05-18","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":12653,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-229656","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526229656/ownership.xml","form_type":"4"}},{"id":772217,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-19T11:30:05.000Z","date":"2026-05-18","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":247588,"source":{"system":"sec-edgar","filing":"0001193125-26-229656","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526229656/ownership.xml","form_type":"4"}},{"id":861806,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date."}],"balance_after":35300,"derivative":{"exercise_price":90.1,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861805,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":447,"price":86.6247,"value":38721.2409,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":232588,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861804,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":1437,"price":85.7807,"value":123266.8659,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":233035,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861803,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":2519,"price":85.0364,"value":214206.6916,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":234472,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861802,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":492,"price":83.9965,"value":41326.278,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":236991,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861801,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":4113,"price":89.6574,"value":368760.8862,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":237483,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861800,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":1424,"price":88.5004,"value":126024.5696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":241596,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861799,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":2039,"price":87.7509,"value":178924.0851,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":243020,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":861798,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:05.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":17650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date."}],"balance_after":245059,"source":{"system":"sec-edgar","filing":"0001193125-26-091982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091982/ownership.xml","form_type":"4"}},{"id":1037908,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-17T21:16:16.000Z","date":"2025-09-17","kind":"exercise","planned":true,"acquired":false,"shares":36974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":36974},"source":{"system":"sec-edgar","filing":"0001193125-25-206350","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525206350/ownership.xml","form_type":"4"}},{"id":1037907,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-17T21:16:16.000Z","date":"2025-09-17","kind":"exercise","planned":true,"acquired":false,"shares":42246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":27653,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":42246},"source":{"system":"sec-edgar","filing":"0001193125-25-206350","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525206350/ownership.xml","form_type":"4"}},{"id":1037906,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-17T21:16:16.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":79220,"price":50.0048,"value":3961380.256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":227409,"source":{"system":"sec-edgar","filing":"0001193125-25-206350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525206350/ownership.xml","form_type":"4"}},{"id":1037905,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-17T21:16:16.000Z","date":"2025-09-17","kind":"exercise","planned":true,"acquired":true,"shares":79220,"price":2.08,"value":164777.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025."}],"balance_after":306629,"source":{"system":"sec-edgar","filing":"0001193125-25-206350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525206350/ownership.xml","form_type":"4"}},{"id":1186554,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-01T12:00:03.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":69899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-048049","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025048049/ownership.xml","form_type":"4"}},{"id":1186553,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-01T12:00:03.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":2.08,"value":52000.0,"ownership":{"direct":true},"balance_after":226886,"source":{"system":"sec-edgar","filing":"0000950170-25-048049","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025048049/ownership.xml","form_type":"4"}},{"id":1236040,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T23:30:05.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":30.17,"expiration_date":"2035-03-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-031146","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025031146/ownership.xml","form_type":"4"}},{"id":1236039,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T23:30:05.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":1281,"price":31.0046,"value":39716.8926,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":201886,"source":{"system":"sec-edgar","filing":"0000950170-25-031146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025031146/ownership.xml","form_type":"4"}},{"id":1236038,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T23:30:05.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":5754,"price":30.3271,"value":174502.1334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":203167,"source":{"system":"sec-edgar","filing":"0000950170-25-031146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025031146/ownership.xml","form_type":"4"}},{"id":1236037,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T23:30:05.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date."}],"balance_after":208921,"source":{"system":"sec-edgar","filing":"0000950170-25-031146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025031146/ownership.xml","form_type":"4"}},{"id":1304366,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-13T12:00:03.000Z","date":"2025-01-10","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":94899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-25-004548","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025004548/ownership.xml","form_type":"4"}},{"id":1304365,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-13T12:00:03.000Z","date":"2025-01-10","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 367 shares acquired under the Registrant's employee stock purchase plan on December 1, 2024"}],"balance_after":178921,"source":{"system":"sec-edgar","filing":"0000950170-25-004548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025004548/ownership.xml","form_type":"4"}},{"id":1467302,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T12:30:03.000Z","date":"2024-06-27","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":104899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-078790","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024078790/ownership.xml","form_type":"4"}},{"id":1467301,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-28T12:30:03.000Z","date":"2024-06-27","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":2.08,"value":52000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 1,203 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024."}],"balance_after":168554,"source":{"system":"sec-edgar","filing":"0000950170-24-078790","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024078790/ownership.xml","form_type":"4"}},{"id":1603447,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T23:12:04.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date."}],"balance_after":187500,"derivative":{"exercise_price":43.5,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000950170-24-025083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024025083/ownership.xml","form_type":"4"}},{"id":1603446,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-04T23:12:04.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":255,"price":43.2564,"value":11030.382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":142351,"source":{"system":"sec-edgar","filing":"0000950170-24-025083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024025083/ownership.xml","form_type":"4"}},{"id":1603445,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-04T23:12:04.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":1301,"price":42.3924,"value":55152.5124,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":142606,"source":{"system":"sec-edgar","filing":"0000950170-24-025083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024025083/ownership.xml","form_type":"4"}},{"id":1603444,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-04T23:12:04.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":2378,"price":41.4135,"value":98481.303,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143907,"source":{"system":"sec-edgar","filing":"0000950170-24-025083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024025083/ownership.xml","form_type":"4"}},{"id":1603443,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-04T23:12:04.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date."}],"balance_after":146285,"source":{"system":"sec-edgar","filing":"0000950170-24-025083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024025083/ownership.xml","form_type":"4"}},{"id":1870195,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T18:17:04.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":129899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-23-025989","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023025989/ownership.xml","form_type":"4"}},{"id":1870194,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T18:17:04.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":115035,"source":{"system":"sec-edgar","filing":"0000950170-23-025989","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023025989/ownership.xml","form_type":"4"}},{"id":1974382,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:30:13.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":142500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date."}],"balance_after":142500,"derivative":{"exercise_price":32.07,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":142500},"source":{"system":"sec-edgar","filing":"0000899243-23-006979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006979/doc4.xml","form_type":"4"}},{"id":1974381,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:13.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":314,"price":31.3973,"value":9858.7522,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":104568,"source":{"system":"sec-edgar","filing":"0000899243-23-006979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006979/doc4.xml","form_type":"4"}},{"id":1974380,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:13.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1056,"price":30.8774,"value":32606.5344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":104882,"source":{"system":"sec-edgar","filing":"0000899243-23-006979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006979/doc4.xml","form_type":"4"}},{"id":1974379,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:30:13.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":23750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 909 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022."}],"balance_after":105938,"source":{"system":"sec-edgar","filing":"0000899243-23-006979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323006979/doc4.xml","form_type":"4"}},{"id":2133028,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-24T12:00:09.000Z","date":"2022-10-21","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":139899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-033996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322033996/doc4.xml","form_type":"4"}},{"id":2133027,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-24T12:00:09.000Z","date":"2022-10-21","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":81279,"source":{"system":"sec-edgar","filing":"0000899243-22-033996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322033996/doc4.xml","form_type":"4"}},{"id":2136399,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-18T00:12:54.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":149899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-033710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322033710/doc4.xml","form_type":"4"}},{"id":2136398,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-18T00:12:54.000Z","date":"2022-10-17","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 465 shares acquired under the Registrant's employee stock purchase plan on May 31, 2022."}],"balance_after":71279,"source":{"system":"sec-edgar","filing":"0000899243-22-033710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322033710/doc4.xml","form_type":"4"}},{"id":2284522,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-03T23:26:30.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":159899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-016429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322016429/doc4.xml","form_type":"4"}},{"id":2284521,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-03T23:26:30.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":20000,"price":2.08,"value":41600.0,"ownership":{"direct":true},"balance_after":60814,"source":{"system":"sec-edgar","filing":"0000899243-22-016429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322016429/doc4.xml","form_type":"4"}},{"id":2355176,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:30:48.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date."}],"balance_after":80000,"derivative":{"exercise_price":38.53,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-009078","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322009078/doc4.xml","form_type":"4"}},{"id":2355175,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:30:48.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date."}],"balance_after":40814,"source":{"system":"sec-edgar","filing":"0000899243-22-009078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322009078/doc4.xml","form_type":"4"}},{"id":2435069,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T22:15:15.000Z","date":"2022-01-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":179899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-002016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002016/doc4.xml","form_type":"4"}},{"id":2435068,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-14T22:15:15.000Z","date":"2022-01-14","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":27514,"source":{"system":"sec-edgar","filing":"0000899243-22-002016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002016/doc4.xml","form_type":"4"}},{"id":2435067,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T22:01:32.000Z","date":"2022-01-12","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones."}],"balance_after":36974,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-002010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002010/doc4.xml","form_type":"4"}},{"id":2435066,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-14T22:01:32.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":1422,"price":53.2678,"value":75746.8116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.01 to $53.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":17514,"source":{"system":"sec-edgar","filing":"0000899243-22-002010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002010/doc4.xml","form_type":"4"}},{"id":2435065,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-14T22:01:32.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":7151,"price":52.1309,"value":372788.0659,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.71 to $52.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":18936,"source":{"system":"sec-edgar","filing":"0000899243-22-002010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002010/doc4.xml","form_type":"4"}},{"id":2435064,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-14T22:01:32.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":6427,"price":51.2135,"value":329149.1645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.70 to $51.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":26087,"source":{"system":"sec-edgar","filing":"0000899243-22-002010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002010/doc4.xml","form_type":"4"}},{"id":2435063,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-14T22:01:32.000Z","date":"2022-01-12","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":32514,"source":{"system":"sec-edgar","filing":"0000899243-22-002010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322002010/doc4.xml","form_type":"4"}},{"id":2486289,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-03T23:43:26.000Z","date":"2021-12-03","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":189899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-046845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321046845/doc4.xml","form_type":"4"}},{"id":2486288,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:43:26.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":300,"price":55.0667,"value":16520.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.96 to $55.12.  Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":17514,"source":{"system":"sec-edgar","filing":"0000899243-21-046845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321046845/doc4.xml","form_type":"4"}},{"id":2486287,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:43:26.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":1987,"price":54.3177,"value":107929.2699,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.92 to $54.74.  Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":17814,"source":{"system":"sec-edgar","filing":"0000899243-21-046845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321046845/doc4.xml","form_type":"4"}},{"id":2486286,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:43:26.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":7713,"price":53.311,"value":411187.743,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.91 to $53.88.  Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":19801,"source":{"system":"sec-edgar","filing":"0000899243-21-046845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321046845/doc4.xml","form_type":"4"}},{"id":2486285,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T23:43:26.000Z","date":"2021-12-03","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 258 shares acquired under the Registrant's employee stock purchase plan on November 30, 2021."}],"balance_after":27514,"source":{"system":"sec-edgar","filing":"0000899243-21-046845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321046845/doc4.xml","form_type":"4"}},{"id":2498534,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-23T21:59:10.000Z","date":"2021-11-23","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":199899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-045803","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321045803/doc4.xml","form_type":"4"}},{"id":2498533,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-23T21:59:10.000Z","date":"2021-11-23","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":17256,"source":{"system":"sec-edgar","filing":"0000899243-21-045803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321045803/doc4.xml","form_type":"4"}},{"id":2579625,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T21:57:15.000Z","date":"2021-09-03","kind":"grant","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":209899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-035158","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321035158/doc4.xml","form_type":"4"}},{"id":2579624,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:57:15.000Z","date":"2021-09-03","kind":"sale","acquired":false,"shares":1500,"price":60.496,"value":90744.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.42 to $60.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":7256,"source":{"system":"sec-edgar","filing":"0000899243-21-035158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321035158/doc4.xml","form_type":"4"}},{"id":2579623,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:57:15.000Z","date":"2021-09-03","kind":"sale","acquired":false,"shares":8500,"price":60.0513,"value":510436.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.41 to $60.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":8756,"source":{"system":"sec-edgar","filing":"0000899243-21-035158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321035158/doc4.xml","form_type":"4"}},{"id":2579622,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:57:15.000Z","date":"2021-09-03","kind":"exercise","acquired":false,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":17256,"source":{"system":"sec-edgar","filing":"0000899243-21-035158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321035158/doc4.xml","form_type":"4"}},{"id":2681155,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T20:16:57.000Z","date":"2021-06-03","kind":"grant","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":219899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-022025","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321022025/doc4.xml","form_type":"4"}},{"id":2681154,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-04T20:16:57.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":4494,"price":47.1273,"value":211790.0862,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.93 to $47.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":7256,"source":{"system":"sec-edgar","filing":"0000899243-21-022025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321022025/doc4.xml","form_type":"4"}},{"id":2681153,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-04T20:16:57.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":5506,"price":46.6591,"value":256905.0046,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.93 to $46.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":11494,"source":{"system":"sec-edgar","filing":"0000899243-21-022025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321022025/doc4.xml","form_type":"4"}},{"id":2681152,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-04T20:16:57.000Z","date":"2021-06-03","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This number includes 256 shares acquired under the Registrant's employee stock purchase plan for the period ended May 31, 2021."}],"balance_after":17256,"source":{"system":"sec-edgar","filing":"0000899243-21-022025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321022025/doc4.xml","form_type":"4"}},{"id":2750512,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-13T22:37:04.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":229899,"derivative":{"exercise_price":2.08,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-21-015650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321015650/doc4.xml","form_type":"4"}},{"id":2750511,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-13T22:37:04.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":7000,"price":2.08,"value":14560.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0000899243-21-015650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321015650/doc4.xml","form_type":"4"}},{"id":2789402,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-16T01:08:10.000Z","date":"2021-03-15","kind":"exercise","acquired":false,"shares":8195,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date"}],"balance_after":234061,"derivative":{"exercise_price":2.08,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":8195},"source":{"system":"sec-edgar","filing":"0000899243-21-011747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011747/doc4.xml","form_type":"4"}},{"id":2789401,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-16T01:08:10.000Z","date":"2021-03-11","kind":"exercise","acquired":false,"shares":1805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date"}],"balance_after":242256,"derivative":{"exercise_price":2.08,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":1805},"source":{"system":"sec-edgar","filing":"0000899243-21-011747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011747/doc4.xml","form_type":"4"}},{"id":2789400,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-16T01:08:10.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":8195,"price":60.1703,"value":493095.6085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.675. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011747/doc4.xml","form_type":"4"}},{"id":2789399,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-16T01:08:10.000Z","date":"2021-03-15","kind":"exercise","acquired":true,"shares":8195,"price":2.08,"value":17045.6,"ownership":{"direct":true},"balance_after":8195,"source":{"system":"sec-edgar","filing":"0000899243-21-011747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011747/doc4.xml","form_type":"4"}},{"id":2789398,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-16T01:08:10.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":1805,"price":60.0731,"value":108431.9455,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011747/doc4.xml","form_type":"4"}},{"id":2789397,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-16T01:08:10.000Z","date":"2021-03-11","kind":"exercise","acquired":true,"shares":1805,"price":2.08,"value":3754.4,"ownership":{"direct":true},"balance_after":1805,"source":{"system":"sec-edgar","filing":"0000899243-21-011747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011747/doc4.xml","form_type":"4"}},{"id":2803509,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-09T01:01:23.000Z","date":"2021-03-08","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":244061,"derivative":{"exercise_price":2.08,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-010463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010463/doc4.xml","form_type":"4"}},{"id":2803508,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-09T01:01:23.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":1,"price":52.15,"value":52.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-010463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010463/doc4.xml","form_type":"4"}},{"id":2803507,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-09T01:01:23.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":2300,"price":51.2767,"value":117936.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1,"source":{"system":"sec-edgar","filing":"0000899243-21-010463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010463/doc4.xml","form_type":"4"}},{"id":2803506,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-09T01:01:23.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":7699,"price":50.4587,"value":388481.5313,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2301,"source":{"system":"sec-edgar","filing":"0000899243-21-010463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010463/doc4.xml","form_type":"4"}},{"id":2803505,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-09T01:01:23.000Z","date":"2021-03-08","kind":"exercise","acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-21-010463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010463/doc4.xml","form_type":"4"}},{"id":2806587,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-05T22:26:08.000Z","date":"2021-03-03","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date."}],"balance_after":254061,"derivative":{"exercise_price":2.08,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-010156","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010156/doc4.xml","form_type":"4"}},{"id":2806586,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T22:26:08.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":1100,"price":45.748,"value":50322.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.60 to $46.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-010156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010156/doc4.xml","form_type":"4"}},{"id":2806585,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T22:26:08.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":12019,"price":45.0703,"value":541699.9357,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.60 to $45.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1100,"source":{"system":"sec-edgar","filing":"0000899243-21-010156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010156/doc4.xml","form_type":"4"}},{"id":2806584,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T22:26:08.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":6881,"price":44.1231,"value":303611.0511,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.56 to $44.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":13119,"source":{"system":"sec-edgar","filing":"0000899243-21-010156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010156/doc4.xml","form_type":"4"}},{"id":2806583,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T22:26:08.000Z","date":"2021-03-03","kind":"exercise","acquired":true,"shares":20000,"price":2.08,"value":41600.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-21-010156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321010156/doc4.xml","form_type":"4"}},{"id":2814501,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T21:27:07.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021."}],"balance_after":140000,"derivative":{"exercise_price":48.46,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000899243-21-009388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321009388/doc4.xml","form_type":"4"}},{"id":3050062,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-21T22:21:59.000Z","date":"2020-08-20","kind":"grant","acquired":true,"shares":32904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness."}],"balance_after":32904,"derivative":{"exercise_price":20,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":32904},"source":{"system":"sec-edgar","filing":"0000899243-20-023227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924320023227/doc4.xml","form_type":"4"}}]}